Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers
Conditions
Interventions
Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Locations
1
United States
Pulmonary Associates, PA
Phoenix, Arizona, United States
Start Date
January 1, 2012
Primary Completion Date
February 1, 2012
Completion Date
February 1, 2012
Last Updated
February 20, 2017
NCT01226316
NCT05907382
NCT03010046
NCT03672604
NCT00854113
NCT01495169
Lead Sponsor
MerLion Pharmaceuticals GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions